These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15816526)

  • 1. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
    Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
    Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M
    Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
    Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
    Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
    Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
    Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
    Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
    Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
    J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse.
    Soos G; Jones RF; Haas GP; Wang CY
    Anticancer Res; 1997; 17(6D):4253-8. PubMed ID: 9494517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
    Sabino MA; Ghilardi JR; Jongen JL; Keyser CP; Luger NM; Mach DB; Peters CM; Rogers SD; Schwei MJ; de Felipe C; Mantyh PW
    Cancer Res; 2002 Dec; 62(24):7343-9. PubMed ID: 12499278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.
    Srinath P; Rao PN; Knaus EE; Suresh MR
    Anticancer Res; 2003; 23(5A):3923-8. PubMed ID: 14666698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
    Whang PG; Gamradt SC; Gates JJ; Lieberman JR
    Prostate Cancer Prostatic Dis; 2005; 8(4):327-34. PubMed ID: 16130017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.